Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom

Postgraduate Medical Journal

Volumn 81, Issue 954, 2005, Pages 252-254

  Lim, C H ^a   Heatley, R V ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEMETACIN; ACETYLSALICYLIC ACID; AZAPROPAZONE; BENORILATE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FENBUFEN; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; SULINDAC; TENOXICAM; TIAPROFENIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; ELDERLY CARE; EROSION; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INGESTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIC ULCER; PRESCRIPTION; PROSPECTIVE STUDY; ULCEROGENESIS; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; ENGLAND; GASTROINTESTINAL HEMORRHAGE; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 17444364887     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.024885     Document Type: Article

References (15)

1. Peterson WL, Cryer B. COX-1-sparing NSAIDs-is the enthusiasm justified? JAMA 1999;282:1961-3.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
3. MHRA/CSM. Non-steroids anti-inflammatory drugs (NSAIDs) and gastrointestinal (GI) safety. Current Problems in Pharmacovigilance 2002;28:5.
4. National Institute for Clinical Excellence. Guidance on the use of cyclooxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: National Institute for Clinical Excellence, 2001:1-18.
5. Office of National Statistics. Census 2001. London: Office of National Statistics, 2003.
6. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering, committee and members of the national audit of acute upper gastrointestinal haemorrhage. BMJ 1995;311:222-6.
7. Rockall TA, Logon RF, Devlin HB, et al. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National audit of acute upper gastrointestinal haemorrhage. Lancet 1996;347:1138-40.
8. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002;50:460-4.
9. Spiro HM. Peptic ulcer: Moynihan's or Marshall's disease? Lancet 1998;352:645-6.
10. Rockall TA, Logon RF, Devlin HB, et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The national audit of acute upper gastrointestinal haemorrhage. Lancet 1995;346:346-50.
11. Longman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
13. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000;284:1247-55.
14. Rockall TA, Logon RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:310-21.
15. MHRA/CSM. Reminder: gastrointestinal toxicity of NSAID. Current Problems in Pharmacovigilance 2003;29:8-9.